Sugi Predict

Sugi Predict / Compounds / SCHEMBL542398

SCHEMBL542398

SCHEMBL542398

CC1(c2ccc(Cl)c(Cl)c2)NC(=O)NC1=O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.55
▸ BACE1 P56817 2/20 0.46
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ TNKS O95271 1/20 0.41
▸ MMP2 P08253 1/20 0.38
▸ ADAMTS5 Q9UNA0 1/20 0.38
▸ AKR1B1 P15121 1/20 0.38
▸ SLC6A4 P31645 6/20 0.37
▸ SLC6A3 Q01959 6/20 0.37
▸ SLC6A2 P23975 5/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968434 0.83 LMNA (0.59) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL7102532 0.81 LMNA (0.47) LMNAAKR1B1
SCHEMBL7102525 0.81 LMNA (0.47) LMNAAKR1B1
SCHEMBL542817 0.80 LMNA (0.51) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL7099930 0.80 LMNA (0.51) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL25400175 0.78 LMNA (0.50) LMNABACE1MEN1KMT2ATNKS
SCHEMBL542805 0.76 LMNA (0.55) LMNABACE1MEN1KMT2ATNKS
SCHEMBL5380796 0.75 AKR1B1 (0.53) LMNAMMP2AKR1B1
SCHEMBL542484 0.75 LMNA (0.70) LMNAMEN1KMT2ATNKSMMP2
SCHEMBL542561 0.74 LMNA (0.53) LMNAMEN1KMT2ATNKSMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235664-A1 PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2025-11-13 — — WO claimed
US-20060182762-A1 Enterovirus, vaccines, medicaments and diagnostic kits AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. (NL) 2006-08-17 — — US claimed
EP-1625214-A1 NEW ENTEROVIRUS, VACCINES, MEDICAMENTS AND DIAGNOSTIC KITS Amsterdam Institute of Viral Genomics B.V. (NL) 2006-02-15 — — EP claimed
WO-2004104189-A1 NEW ENTEROVIRUS, VACCINES, MEDICAMENTS AND DIAGNOSTIC KITS AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. (NL) 2004-12-02 — — WO claimed
US-20260124226-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-05-07 — — US disclosed
EP-4705284-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Emory University (US) 2026-03-11 — — EP disclosed
WO-2024233354-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2024-11-14 — — WO disclosed
US-11945811-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-04-02 — — US disclosed
CN-117561247-A Novel potassium channel inhibitors 阿塞西翁制药公司 2024-02-13 — — CN disclosed
EP-4313973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2024-02-07 — — EP disclosed
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-21 — — US disclosed
WO-2022200162-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACECION PHARMA APS (DK) 2022-09-29 — — WO disclosed
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER KOWA COMPANY, LTD. (JP) 2010-02-25 — — US disclosed
EP-2114906-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. Hoffmann-Roche AG (CH) 2009-11-11 — — EP disclosed
EP-2098515-A1 SUBSTITUTED CARBINOL COMPOUND Kowa Company. Ltd. (JP) 2009-09-09 — — EP disclosed
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands F. HOFFMANN-LA ROCHE AG (CH) 2008-10-23 — — US disclosed
WO-2008092785-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-07 — — WO disclosed
US-20060182762-A1 Enterovirus, vaccines, medicaments and diagnostic kits AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. (NL) 2006-08-17 — — US disclosed
EP-1625214-A1 NEW ENTEROVIRUS, VACCINES, MEDICAMENTS AND DIAGNOSTIC KITS Amsterdam Institute of Viral Genomics B.V. (NL) 2006-02-15 — — EP disclosed
WO-2004104189-A1 NEW ENTEROVIRUS, VACCINES, MEDICAMENTS AND DIAGNOSTIC KITS AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. (NL) 2004-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945811-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 LMNA 566/4885BACE1 2781/4885MEN1 994/4885
US-20060182762-A1 Enterovirus, vaccines, medicaments and diagnostic kits CD99, CD63, FAM83B LMNA 2140/4885BACE1 4141/4885MEN1 659/4885
US-20260124226-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO NSUN2, SARS1, SNRPE LMNA 1728/4885BACE1 4573/4885MEN1 4825/4885
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER NR1H2, NR1H3, LDLR LMNA 1288/4885BACE1 58/4885MEN1 3823/4885
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 LMNA 847/4885BACE1 2575/4885MEN1 1536/4885
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands TAAR1, TAAR5, NPY2R LMNA 3654/4885BACE1 244/4885MEN1 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.